
Unicycive Therapeutics fell 33.0% from $5.27 to $3.53, behind the S&P 500's +9.7%. Its worst day was Jun 30 (−39.1%), and its low came Oct 16 at $3.36.
Nov 20, 2025 – Nov 19, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.82 missed the $-0.46 estimate on $0.00 revenue (est. $590,860.00).
−4.4% · S&P 500 −0.3%
EPS of $-0.54 missed the $-0.49 estimate on $0.00 revenue (est. $14.3M).
Story events cover the past 12 months · Times ET
+2.8% · S&P 500 −0.2%
Unicycive Therapeutics shares fell 12.6%, while the S&P 500 rose 0.7%.
−12.6% · S&P 500 +0.7%
Unicycive Therapeutics shares rose 14.9%, while the S&P 500 fell 0.3%.
+14.9%, the year's best day · S&P 500 −0.3%
Unicycive Therapeutics shares fell 39.1%, while the S&P 500 rose 0.8%.
−39.1%, the year's worst day, on 20M shares, the year's heaviest volume · S&P 500 +0.8%
EPS of $-0.06 beat the $-0.33 estimate on $0.00 revenue (est. $28.6M).
+7.8% · S&P 500 +0.3%
Unicycive Therapeutics closed at its lowest level of the year, 36.2% below where the year started.
−6.4% · S&P 500 −1.1%
EPS of $-0.25 beat the $-0.35 estimate on $0.00 revenue (est. $1.2M).
+4.2% · S&P 500 −1.9%
Where it ended: a close of $3.53 on Nov 19, 2026.
Nothing in the past 12 months.
All UNCY dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for UNCY and SPY from Benzinga historical bars. Not investment advice.